Public Policy Resources

Share

As a recognized expert in cancer health policy, ACS CAN develops reports, white papers, testimony, fact sheets, regulatory comment letters and public policy on a wide range of issues related to preventing cancer and improving the health care system for persons with cancer and survivors.  We encourage you to use this resource to learn more about our issue priorities and policy work. If you can't find something you need, you may contact us by using our contact form and selecting Policy Resources from the drop-down menu.

Search for Resources

FILTER BY:

Woman seeing her physician

Access to Health Care

ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.

ACS CAN Comments to CMS re: Montana 1115 Waiver

October 17, 2025

ACS CAN submitted comments to CMS opposing Montana's 1115 waiver application to implement work requirements and premiums in their Medicaid program.

Medicaid Work Requirements Jeopardize Cancer Patients & Survivors

October 8, 2025

ACS CAN opposes policies that condition Medicaid enrollment on work or reporting of work. 

Group Letter Supporting MCED Legislation

September 24, 2025

ACS CAN joined with 50 other organizations to applaud Representatives Jodey Arrington (R-TX) and Terri Sewell (D-AL) for sponsoring and prioritizing the passage of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 842).

View All Access to Health Care Resources

Photo of ACS CAN Volunteers at Advocacy Event to Support Cancer Research Funding

Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

Survivor Views on Artificial Intelligence and FDA Medical Product Reviews

September 14, 2025

Our latest survey finds 80% of cancer patients and survivors agree that industries making FDA-regulated products should provide some of the cost of FDA’s public health oversight. The survey also reveals hesitency toward the increased use of AI, mirroring the sentiment of the American public. Cancer patients and survivors offer tempered support for the use of AI in FDA product reviews if funding cuts extend review times, with a plurality undecided on whether they support or oppose it.

Community Support Letter for Clinical Trial Modernization Act 119th Congress

August 18, 2025

Over 130 organizations have endorsed the Clinical Trial Modernization Act (H.R. 3521).  The legislation would address known barriers to cancer clinical trial participation, enabling financial and technical support of patients enrolled on trials while protecting them from unexpected tax burdens from that support. 

ACS CAN Supports the Clinical Trial Modernization Act (H.R. 3521)

May 22, 2025

The Clinical Trial Modernization Act (H.R. 3521) increase access to clinical trials by allowing clinical trial sponsors to provide financial support to patients for costs associated with their trial participation, including medical cost-sharing like copays, and non-medical expenses such as travel, parking, food and lodging.

View All Research, Funding and Drug Development Resources

Photo of Making Strides Against Breast Cancer Event Participant

Prevention and Early Detection

ACS CAN advocates for public policies that can prevent nearly half of all cancer deaths by ensuring access to recommended cancer screenings, protecting the public from skin cancer risk, reducing tobacco use and exposure to secondhand smoke and supporting people in increasing physical activity, eating a healthy diet, and managing their weight.

ACS CAN Comments to the Advisory Committee on Immunization Practices (ACIP)

September 19, 2025

ACS CAN supports fact-based vaccine policies that fight cancer through increased access and uptake of vaccines that prevent viruses that lead to cancer, treat cancer by boosting the immune system, and protect cancer patients and their families by maximizing community immunity.

Congress Should Reauthorize the Young Women’s Breast Health Education and Awareness Requires Learning Young Act (EARLY ACT 2025)

August 29, 2025

Young women in the U.S. are increasingly being diagnosed with breast cancer. About 16% of all new cases of breast
cancer in the U.S. are in women younger than 50. The impact on young women’s lives can be devastating, as breast

The Critical Role of Preventive Services without Cost Sharing for Cancer Prevention and Survivorship

August 20, 2025

Access to preventive services saves lives. Over the past four decades, cancer prevention and screening services alone have averted approximately 4.75 million deaths from breast, cervical, colorectal, lung and prostate cancers.

View All Prevention and Early Detection Resources

Doctor and Patient

Health Equity

ACS CAN supports health equity efforts for all Americans so they may receive access to quality care, no matter their race, ethnicity, sexual orientation, income level or ZIP code. 

Increasing Access to Cancer Screenings for Individuals with Disabilities

September 30, 2025

For the American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN), health equity means that everyone has a fair and just opportunity to prevent, detect, treat, and survive cancer – no matter how much money someone makes, the color of their skin, sexual orientat

Solo los datos: Desigualdades en el cáncer de seno

May 29, 2025

El cáncer de seno es el tipo de cáncer que se diagnostica con mayor frecuencia en mujeres en EE.UU. Aunque en lasúltimas décadas se han logrado avances sustanciales en la reducción de la mortalidad por esta enfermedad,persisten desigualdades, especialmente entre las mujeres de raza negra.

ACS, ACS CAN and Partners Joint Comments on Patient Navigation Provisions of CY2025 Medicare Physician Fee Schedule Proposed Rule

September 9, 2024

The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) along with partners appreciate the opportunity to comment on the Patient Navigation provisions of CY2025 Medicare Physician Fee Schedule.

View All Health Equity Resources